Early PReserved SPONtaneous Breathing Activity in Mechanically Ventilated Patients With ARDS (PReSPON)

Last updated: February 8, 2021
Sponsor: University Hospital, Bonn
Overall Status: Active - Recruiting

Phase

N/A

Condition

Acute Respiratory Distress Syndrome (Ards)

Lung Injury

Treatment

N/A

Clinical Study ID

NCT04228471
UKB_PReSPON
  • Ages > 18
  • All Genders

Study Summary

The potential benefits of preserved early spontaneous breathing activity during mechanical ventilation are an increased aeration of dependent lung regions, less need for sedation, improved cardiac filling, and better matching of pulmonary ventilation and perfusion and thus oxygenation. Two small randomized controlled trials (RCTs) in patients with acute respiratory distress syndrome (ARDS) reported less time on mechanical ventilation and in the intensive care unit (ICU) with preserved early spontaneous breathing activity during Airway Pressure Release Ventilation (APRV).

Debate exists over the net effects of preserved early spontaneous breathing activity with regard to ventilator-associated lung injury (VALI). In fact, by taking advantage of the potential improvement in oxygenation and recruitment at lower inflation pressures associated with APRV, physicians could possibly reduce potentially harmful levels of inspired oxygen, tidal volume, and positive end-expiratory pressure (PEEP). However, spontaneous breathing during mechanical ventilation has the potential to generate less positive pleural pressures that may add to the alveolar stretch applied from the ventilator and contribute to the risk of VALI. This has led to an ongoing controversy whether an initial period of controlled mechanical ventilation with deep sedation and neuromuscular blockade or preserved early spontaneous breathing activity during mechanical ventilation is advantageous with respect to outcomes in ARDS patients.

A RCT investigating the effects of early spontaneous breathing activity on mortality in moderate to severe ARDS has been highly recommended in the research agenda for intensive care medicine.

The objective of this study is to evaluate the efficacy and safety of preserved spontaneous breathing activity during APRV in the early phase of moderate to severe ARDS.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Moderate to severe ARDS for ≤ 48 hours according to the Berlin definition will bedefined by acute onset of:
  2. PaO2/FiO2 ≤ 200 mmHg (equivalent to ≤ 26.7 kPa) under invasive mechanicalventilation with PEEP ≥ 5 cmH2O
  3. Bilateral infiltrates documented by chest radiograph
  4. Not fully explained by cardiac failure or fluid overload (e.g. echocardiography)
  5. Requirement for positive pressure ventilation via an endotracheal tube/ tracheotomy
  6. Presence of informed consent according to local regulations
  7. Age ≥ 18 years
  8. Expected duration of mechanical ventilation > 48 hours at randomization

Exclusion

Exclusion Criteria:

  1. Need of extracorporeal lung support, high frequency oscillation and/or inhaledvasodilators for severe hypoxemia prior to inclusion
  2. Woman known to be pregnant, lactating or having a positive or indeterminate pregnancytest
  3. Neuromuscular disease that impairs ability to ventilate spontaneously
  4. Severe chronic respiratory disease (e.g. COPD, pulmonary fibrosis, and other chronicdiseases of the lung, chest wall or neuromuscular system) requiring home oxygentherapy or mechanical ventilation (non-invasive ventilation or via tracheotomy) exceptfor Continuous Positive Airway Pressure (CPAP) or non-invasive Biphasic PositiveAirway Pressure (BiPAP) used solely for sleep-disordered breathing
  5. Chronic kidney disease stage V (requirement of dialysis) according to the K/DOQIdefinition of chronic kidney disease
  6. Massive diffuse alveolar haemorrhage
  7. Recent lung transplant < 12 months
  8. Morbid obesity defined as weight greater than 1 kg / cm
  9. Burns > 70% total body surface
  10. Suspected or known elevated intracranial pressure
  11. Chronic liver disease (Child-Pugh grade C)
  12. Ongoing chemotherapy and/or bone marrow transplantation within the last 3 months
  13. Moribund patient not expected to survive 48 hours
  14. Patients not expected to survive 90 days on the basis of the premorbid health status
  15. Patient, surrogate, or physician not committed to full life support

Study Design

Total Participants: 840
Study Start date:
February 08, 2020
Estimated Completion Date:
July 31, 2024

Connect with a study center

  • University Hospital Bonn, Department of Anesthesiology and Critical Care Medicine

    Bonn, 53127
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.